Treatment Centers
Treatment Centers and Clinical Trials
You can restrict your search to only Treatment Centers or only Clinical Trials by checking the Treatment Center or Clinical Trial checkbox under TYPE. Use the Zoom-In (+ sign on the lower right of the map) to enlarge the map area to find your preferred location. To search for a Treatment Center or Clinical Trial, click on the red map pin for the name of the facility. Click on the name of the facility for more details.
Location
Treatments/Services
Type
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
The Warren Alpert Medical School of Brown University, Department of Dermatology
Providence, RI, United States
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
University of Virginia-Emily Couric Clinical Cancer Center
Charlottesville, VA, United States
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Washington University Medical Center - Siteman Cancer Center
St Louis, MO, United States
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Center for Cutaneous Oncology at Dana Farber/Brigham and Women's Cancer Center
Boston, MA, United States
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Columbia University Irving Medical Center - Cutaneous Lymphoma Center
New York, NY, United States
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Duke Cutaneous T-Cell Lymphoma Clinic and Research Center
Durham, NC, United States
Treatment Centers
UCHealth - University of Colorado Cancer Center - Anschutz
Aurora, CO, United States
Treatment Centers
Treatment Centers
Stanford Medical Center (Multidisciplinary Cutaneous Lymphoma Clinic)
Stanford, CA, United States
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Emil P. Bisaccia, MD, Center for Photopheresis at Morristown Medical Center
Morristown, NJ, United States
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Treatment Centers
Clinical Trials
Lacutamab - TELLOMAK Study
An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of lacutamab (IPH4102) alone or in combination with chemotherapy in patients with advanced t-cell lymphoma
Clinical Trial Name: IPH4102-201 / TELLOMAK study
Clinical Trial Description:
Clinical Trials
TTI-621 - Study
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Brief Summary
Multicenter, open-label, phase 1a/1b trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
Clinical Trials
Clinical Trials
Pembrolizumab - Stage IB-IV Mycosis Fungoides
Brief Summary:
This phase II trial studies how well pembrolizumab works in treating patients with stage IB-IV mycosis fungoides. Antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread.
Website: https://clinicaltrials.gov/ct2/show/NCT03695471?term=mc1788&draw=2&rank=1
PRIMARY OBJECTIVE:
Clinical Trials
Mogamulizumab Q4week Dosing
Brief Summary:
This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of mogamulizumab given Q4W following initial weekly induction in adult participants with relapsed/refractory MF and SS subtypes of CTCL. The study is composed of a 28-day Screening Period during which participants are screened for entry into this study, followed by a treatment period of up to 2 years from Cycle 1 Day 1.
Clinical Trials
Dose-Escalation Trial Evaluating CPI-818
Brief Summary:
This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability, and anti-tumor activity of CPI-818 as a single drug. This trial is composed of dose escalation and dose expansion cohorts.
Clinical Trials
Clinical Trials
Clinical Trials
Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
Brief Summary:
Clinical Trials
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTC
Brief Summary:
This is an international, multicenter, multi-arm, phase Ib, model-based dose-escalation study. The primary objectives of the study in each arm is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose limiting toxicities (DLTs) and to evaluate the clinical efficacy at the MTD of various combinations of pembrolizumab, pralatrexate and decitabine.
Clinical Trials